Literature DB >> 8975855

Cost and efficacy of surgical ligation versus transcatheter coil occlusion of patent ductus arteriosus.

J A Hawkins1, L L Minich, L Y Tani, J E Sturtevant, G S Orsmond, E C McGough.   

Abstract

OBJECTIVE: The purpose of this study was to compare cost and efficacy of surgical closure of patent ductus arteriosus using new critical pathway methods with outpatient transcatheter coil occlusion of patent ductus arteriosus.
METHODS: Surgical techniques included a transaxillary, muscle-sparing thoracotomy, triple ligation of the patent ductus arteriosus, no chest tube, and discharge from the hospital within 24 hours. Transcatheter coil occlusion of patent ductus arteriosus was done as an outpatient procedure. Costs were compared with inclusion of all hospital and professional charges.
RESULTS: From July 1994 until March 1996, 20 patients underwent coil occlusion of patent ductus arteriosus and 20 patients underwent surgical closure of patent ductus arteriosus. Duration of hospitalization was significantly less for the patients receiving coil occlusion (11 +/- 6 hours) as compared with that for the patients having surgical ligation (28 +/- 7 hours, p < 0.05). Total charges were similar for surgical ligation ($7101 +/- $408) as compared with those for coil occlusion ($7104 +/- $886, p > 0.05). Morbidity in coil occlusion included inability to occlude the patent ductus arteriosus in two patients (2/20, 10%) and residual patency in two patients (2/18, 11%). Morbidity in the surgical group included nausea and vomiting necessitating hospitalization for more than 36 hours in one patient (1/20, 5%), transient left recurrent laryngeal nerve palsy in one (1/20, 5%), and pneumothorax in two patients (2/20, 10%). There were no instances of residual patency in the surgical group.
CONCLUSIONS: Transaxillary thoracotomy without tube thoracostomy and with critical pathway methods allows safe and effective ligation of a patent ductus arteriosus with early hospital discharge. This surgical method has similar cost, higher efficacy rate, and applicability in all patients as compared with newer transcatheter coil occlusion techniques for closure of a patent ductus arteriosus.

Entities:  

Mesh:

Year:  1996        PMID: 8975855     DOI: 10.1016/S0022-5223(96)70022-3

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Embolization of Gianturco coil into the pulmonary artery requiring emergency surgical intervention.

Authors:  A Hijazi; R Mazhar; V Bricelj; A Robida
Journal:  Tex Heart Inst J       Date:  1999

2.  Catheter interventions in congenital heart disease without regular catheterization laboratory equipment: the chain of hope experience in Rwanda.

Authors:  John Senga; Emmanuel Rusingiza; Joseph Mucumbitsi; Agnès Binagwaho; Bert Suys; Christine Lys; Karlien Carbonez; Caroline Ovaert; Thierry Sluysmans
Journal:  Pediatr Cardiol       Date:  2012-05-27       Impact factor: 1.655

3.  Profound Bradycardia following Patent Ductus Arteriosus Closure; A Rare but Correctable Event.

Authors:  Khalil Zarrabi; Parsa Ravanfar; Azimeh Azimifar; Fariborz Ghaffarpasand
Journal:  Bull Emerg Trauma       Date:  2013-07

4.  Comparison of long-term clinical outcomes and costs between video-assisted thoracoscopic surgery and transcatheter amplatzer occlusion of the patent ductus arteriosus.

Authors:  Haiyu Chen; Guoxing Weng; Zhiqun Chen; Huan Wang; Qi Xie; Jiayin Bao; Rongdong Xiao
Journal:  Pediatr Cardiol       Date:  2011-10-22       Impact factor: 1.655

5.  Comparison of cost-effectiveness and postoperative outcome of device closure and open surgery closure techniques for treatment of patent ductus arteriosus.

Authors:  Alireza Ahmadi; Mohammadreza Sabri; Hamid Bigdelian; Bahar Dehghan; Mojgan Gharipour
Journal:  ARYA Atheroscler       Date:  2014-01

6.  Thoracoscopic ligation versus coil occlusion for patent ductus arteriosus: a matched cohort study of outcomes and cost.

Authors:  Sanjeev Dutta; Alexandra Mihailovic; Lee Benson; Paul F Kantor; Peter G Fitzgerald; J Mark Walton; Jacob C Langer; Brian H Cameron
Journal:  Surg Endosc       Date:  2007-11-20       Impact factor: 4.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.